Evidence map›Paper›PMID 32354890›Full record

ArticleIn vivo (Athens, Greece)

Prophylactic Effect of Recombinant Human Soluble Thrombomodulin for Hepatic Sinusoidal Obstruction Syndrome Model Mice.

Shunsuke Kanou, Tomoharu Miyashita, Yasuhiko Yamamoto, Satoshi Takada, Makoto Nakura, Mitsuyoshi Okazaki, Yoshinao Ohbatake, Shinichi Nakanuma, Isamu Makino, Hidehiro Tajima and 3 more

Open access · diamondAbstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Shunsuke KanouDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Tomoharu MiyashitaDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan tomoharumiya@gmail.com.
Yasuhiko YamamotoDepartment of Biochemistry and Molecular Vascular Biology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
Satoshi TakadaDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Makoto NakuraDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Mitsuyoshi OkazakiDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Yoshinao OhbatakeDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Shinichi NakanumaDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Isamu MakinoDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Hidehiro TajimaDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Hiroyuki TakamuraDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Sachio FushidaDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Tetsuo OhtaDepartment of Gastroenterological Surgery, Kanazawa University Hospital, Kanazawa, Japan.
Kanazawa University Hospital · JPKanazawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe present study aimed to examine the effects of prophylactic administration of recombinant human soluble thrombomodulin (rTM) for the prevention of sinusoidal obstruction syndrome (SOS). MATERIALS AND

methodsCrl:CD1 mice were allocated to the rTM, placebo, and control groups. The rTM group received an intraperitoneal administration of rTM, with intraperitoneal administration of monocrotaline (MCT) 1 h later. The placebo group received PBS instead of rTM, and the control group received PBS instead of rTM and MCT. Mice were sacrificed 48 h after MCT administration, and blood and liver tissues were evaluated. Immunostaining was performed using anti-CD42b and anti-SE-1 antibodies, and AZAN staining. Levels of plasminogen activator inhibitor (PAI-1) and endothelial nitric oxide synthase (eNOS) in whole liver tissues were estimated using RT-PCR.

resultsHematoxylin-eosin staining showed that SOS-related findings were markedly attenuated in the rTM group compared to the placebo group. CD42b immunostaining showed the presence of extravasated platelet activation (EPA) in the Disse space in the placebo group, but this was less noticeable in the rTM group. PAI-1 levels were significantly lower in the rTM group than in the placebo group in RT-PCR. However, eNOS levels were significantly higher in the rTM group than in the placebo group.

conclusionAdministration of rTM may prevent SOS by protecting sinusoidal endothelial cells.

Indexed as

AnimalsBiomarkersBiopsyBlood Cell CountDisease Models, AnimalHepatic Veno-Occlusive DiseaseHumansImmunohistochemistryLiverMicePre-Exposure ProphylaxisRecombinant ProteinsThrombomodulinTreatment OutcomeBiomarkersRecombinant ProteinsTHBD protein, humanThrombomodulinliver sinusoidal endothelial cellsprophylactic effectrecombinant human soluble thrombomodulinSinusoidal obstruction syndrome (SOS)SOS mouse model

Identifiers

PMID32354890
PMCPMC7279798
OpenAlexW3022028374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.